R&D channel feed

Rat­tle and hum: Roche, PTC post up­date on their SMA drug as a shak­en Bio­gen faces yet an­oth­er fran­chise buster

7 years ago
Pharma
Cell/Gene Tx

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

7 years ago
People
Pharma

Catch­ing Cat­a­lyst Phar­ma by sur­prise, FDA ap­proves Ja­cobus LEMS drug for pe­di­atric pa­tients — based on adult da­ta

7 years ago
Pharma

Watch out Ab­b­Vie and J&J, As­traZeneca just took an­oth­er big swing at one of your star can­cer drug fran­chis­es

7 years ago
Pharma

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

7 years ago
People

GW Phar­ma scores an­oth­er PhI­II win for its cannabi­noid in rare form of epilep­sy

7 years ago

Bill Haney's Sky­hawk spears an­oth­er mar­quee al­liance for its work drug­ging RNA in Take­da neu­ro pact

7 years ago
People
Pharma

Pfiz­er en­ters Al­ny­lam, Ion­is' TTR turf with ear­ly ap­proval for car­diomy­opa­thy drug, car­ry­ing a $225K price tag

7 years ago
Pharma

Hit by set­backs, Lund­beck­'s Deb­o­rah Dun­sire inks a $400M cannabi­noid buy­out, adding a dis­cov­ery site

7 years ago
People
Deals

New Zol­gens­ma da­ta sug­gest com­pa­ra­ble ef­fi­ca­cy to Spin­raza — an­a­lysts

7 years ago
Cell/Gene Tx

Cy­to­ki­net­ic­s' come­back at­tempt with sec­ond-gen mus­cle drug is slammed by a PhII fail­ure in ALS

7 years ago

Genky­otex picks out sil­ver lin­ings from failed PhII, braces for piv­otal study in pri­ma­ry bil­iary cholan­gi­tis

7 years ago

Mi­cro­cap biotech Vista­Gen turned to pen­ny­s­tock af­ter PhII re­sults show its de­pres­sion drug does­n't work so­lo

7 years ago

As back­lash mounts in the wake of a dis­as­trous PhI­II flop, Ei­sai goes deep­er with 2 new hires

7 years ago
People
Pharma

Dan O’Day’s to-do list for Gilead: Re­cruit a Kite CEO, press the ped­al on next-gen cell ther­a­pies and start buy­ing stuff

7 years ago
People

Weeks af­ter a Pfiz­er/Mer­ck KGaA break­down, Clo­vis gam­bles on a $175M loan to fin­ish a glob­al PhI­II PARP/PD-1 com­bo study

7 years ago
Financing

As­traZeneca bets cau­tious­ly on on­colyt­ic virus dis­cov­ery pro­gram, out­lin­ing $13M deal with Trans­gene

7 years ago
Discovery

Go­ing glob­al, Take­da opens up 165,000-square-foot R&D fa­cil­i­ty in San Diego

7 years ago

Ter­ry Rosen is look­ing to leave the thun­der­ing herd and blaze a new trail in PD-1 R&D

7 years ago
People

The BC­MA fren­zy: Track­ing the 37 drugs around the world rac­ing to over­take blue­bird bio and Cel­gene

7 years ago

Why did GSK kill two vac­cine R&D pro­grams? CEO Em­ma Walm­s­ley is glad you asked

7 years ago

Man­u­fac­tur­ing con­cerns spike Nabri­va’s plans to launch its first an­tibi­ot­ic — for now

7 years ago

In­cyte pulls away 'dam­aged good­s' baric­i­tinib to fo­cus on in­ter­nal pipeline

7 years ago

Suf­fer­ing a se­ries of set­backs, Eli Lil­ly's on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

7 years ago
First page Previous page 246247248249250251252 Next page Last page
A service from the Financial Times